Z-drug abuse and dependence: clinical guideline of the Brazilian Academy of Neurology for diagnosis and management
Open accessThe DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index; 60 of the 159 sources its claims cite were checked for support.
Abstract
Benzodiazepine (BZD) receptor agonists, commonly known as Z-drugs, are non-BZD hypnotics primarily prescribed for the treatment of insomnia. Their use is recommended for no longer than four weeks to minimize the risk of adverse effects, including dependence and withdrawal. However, these guidelines are frequently disregarded, and the abuse of and dependence on Z-drugs has emerged as a growing public health concern in Brazil. The present article reviews the current evidence on Z-drug use disorder-including dependence and withdrawal-and proposes clinical guidelines for the management of discontinuation. The recommendations were developed based on a systematic review of the literature and refined using the Delphi methodology. The consensus was developed by a multidisciplinary task force, with coordination and voting led by a steering committee. An advisory committee, consisting of neurologists from the Brazilian Academy of Neurology (Academia Brasileira de Neurologia, ABN, in Portuguese) and psychiatrists specializing in substance-use disorders, contributed to the selection and organization of the scientific literature and took part in the voting process. Key recommendations were established: 1) prior to discontinuation, a comprehensive assessment of mental status, psychiatric and sleep comorbidities, and the degree of pharmacological dependence is essential; 2) gradual tapering is advised; 3) non-pharmacological interventions, such as cognitive behavioral therapy for insomnia, are recommended, and acceptance and commitment therapy, which is optional, may be incorporated; 4) for zolpidem withdrawal, adjunctive pharmacotherapy, which is optional, may include trazodone, other antidepressants, quetiapine or other antipsychotics, alpha-2-delta (α2δ) ligands, or alternative hypnotics (such as ramelteon, zopiclone, and eszopiclone); 5) for Z-drug discontinuation, intermediate- or long-acting BZDs are recommended; and 6) short- or ultra-short-acting BZDs and immediate-release melatonin are not recommended. © 2025 Associacao Arquivos de Neuro-Psiquiatria. All rights reserved.
Overview
CoChat Summary
## TL;DR
This Brazilian Academy of Neurology guideline reviews evidence on Z-drug dependence and withdrawal and proposes Delphi-based recommendations for deprescribing. It concludes that assessment of comorbidities and dependence severity is essential, gradual tapering is advised, CBT-I is recommended, and adjunctive pharmacotherapy is only optional in selected cases.
## Key findings
- The guideline developed 29 PICO research questions: 18 on deprescribing, 4 on abstinence, and 7 on dependence/abuse.
- The deprescribing review included 13 articles; only 6 were randomized controlled trials (RCTs). The abstinence review included 38 articles, 30 of which were case reports. The dependence review included 24 articles.
- The highest level of evidence was level 2 for PICO 1.1 (effect of CBT-I on weaning from Z-drugs for insomnia); all other questions were rated levels 3 to 5.
- In a systematic review of Z-drug withdrawal cases, the authors identified 43 reports published between 1990 and 2025; 93.0% involved zolpidem, 7.0% zopiclone, and none involved zaleplon or eszopiclone. Among seizure cases, 24 epileptic seizures were described, with a median maximum dose of 250 mg and a median abstinence period of 30 hours before seizure onset.
## Methods
- Design: Clinical guideline/consensus statement developed from systematic reviews and refined using the Delphi method, with evidence graded using the Oxford Centre for Evidence-Based Medicine (OCEBM) levels.
- Data/sample: The task force created 29 PICO questions and reviewed articles for deprescribing, abstinence, and dependence/abuse; the final evidence base included 13 deprescribing articles, 38 abstinence articles, and 24 dependence articles.
- Main analysis: Articles were individually assigned evidence levels, then recommendations were voted on in up to three Delphi rounds with a 66% consensus threshold; a steering committee and advisory committee reviewed all items and could modify consensus status.
## Limitations
- The paper explicitly states that meta-analyses could not be performed because of the limited number of studies and high methodological heterogeneity.
- It also states that the evidence base is generally low quality and that many recommendations rely on expert opinion because of the scarcity of high-level studies.
- The paper notes that many experts had limited or no experience with medications not available in Brazil (such as DORAs and extended-release melatonin), which may have influenced recommendations; it also says not all psychotherapeutic approaches were evaluated and that the absence of psychologists with expertise in those modalities may have limited the non-pharmacological recommendations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
44 Valid · 6 Not valid · 54 Not checked · 57 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Advancing age has been associated with an increased risk of developing Z-drug use disorder.”
§ Z-drug abuse and dependence: clinical guideline of the Brazilian Academy of Neurology for diagnosis and management > CONSENSUS > Risk factors for Z-drug use disorder
What the sources say
- Supportedcites [9] F Schifano, 2019, An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions, Int J Neuropsychopharmacol sourceExperimental — accuracy not yet measured
Schifano’s paper analyzes Z-drug abuse and dependence, including patients’ ages, although the paper-scoped searches did not find a direct statement linking advancing age to greater risk. The Brazilian Academy of Neurology’s clinical guideline states the claim verbatim (score 0.877) and cites reference 9 for it. Another passage in that guideline identifies reference 9 as Schifano et al., supporting confirmation through a secondary citation rather than an exact match in Schifano’s text. (LLM, conf=0.78)
- Could not verifycites [44] R A Ellis, 2024, Age and gender differences in motives for z-drug misuse: Findings from the 2015 to 2019 NSDUH survey, Am J Addict sourceExperimental — accuracy not yet measured
Two searches of Ellis’s paper returned no snippets, so its findings could not be checked against the claim. An unscoped search found the exact sentence in “Z-drug abuse and dependence: clinical guideline of the Brazilian Academy of Neurology for diagnosis and management” (score 0.716), but the sentence cites other studies; the available results do not show whether Ellis is among them. The match therefore does not establish that the claim was misattributed. (LLM, conf=0.63)
- Partly supportedcites [50] S Cheng, 2019, Sociodemographic, clinical and pharmacological profiles of medication misuse and dependence in hospitalised older patients in Norway: a prospective cross-sectional study, BMJ Open sourceExperimental — accuracy not yet measured
The Results (Factors associated with prolonged use of CNSDs; page unavailable) associate older age with prolonged use of CNS depressants, a group that includes z-hypnotics. The Results (Factors associated with CNSD misuse or dependence; page unavailable) instead identify pain intensity and concurrent CNS-depressant use as associated with misuse or dependence. The paper does not establish an age-related increase in risk of developing Z-drug use disorder. (LLM, conf=0.87)
states an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In contrast, eszopiclone has demonstrated safety for up to 12 months in primary insomnia patients.”
§ Z-drug abuse and dependence: clinical guideline of the Brazilian Academy of Neurology for diagnosis and management > INTRODUCTION
What the sources say
- Partly supportedcites [4] M J Sateia, 2017, Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American academy of sleep medicine clinical practice guideline, J Clin Sleep Med sourceExperimental — accuracy not yet measured
The Summary (page not provided) describes a low potential for adverse events with eszopiclone. However, the Discussion (page not provided) describes studies lasting up to six months, not 12 months, so the claimed duration of demonstrated safety is unsupported. (LLM, conf=0.88)
- Partly supportedcites [5] D Riemann, 2023, The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023, J Sleep Res sourceExperimental — accuracy not yet measured
Section 4.2.1 (p. 17) says eszopiclone has long-term data extending to 12 months, but it does not say safety was demonstrated for that duration or specify that those data concern patients with primary insomnia. Instead, it advises caution beyond four weeks. Section 4.2.8 (p. 22) also finds the evidence insufficient for a general recommendation for longer-term medication use. (LLM, conf=0.88)
- Supportedcites [6] L F Drager, 2023, 2023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults - Brazilian Sleep Association, Sleep Sci source
The eszopiclone section reports that eszopiclone was found to be a safe therapeutic option and says Roth and Walsh described the same results with 12-month follow-up. The References section identifies that study as an evaluation of eszopiclone’s efficacy and safety in patients with chronic primary insomnia. The guidelines note that the final six months were open-label. (LLM, conf=0.86)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In young adults, low level of schooling and use of alcohol, tobacco, and illicit drugs correlate with the inappropriate use of sedatives and hypnotics.”
§ Z-drug abuse and dependence: clinical guideline of the Brazilian Academy of Neurology for diagnosis and management > CONSENSUS > Risk factors for Z-drug use disorder
What the sources say
- Partly supportedcites [43] D Palacios-Ceña, 2019, Time trends in the co-use of cannabis and the misuse of tranquilizers, sedatives and sleeping pills among young adults in Spain between 2009 and 2015, Int J Environ Res Public Health sourceExperimental — accuracy not yet measured
The Conclusions (page not provided) associate lack of education and use of alcohol, tobacco, and other illicit drugs with greater consumption among young adults. However, the study’s outcome is specifically the co-use of cannabis with misuse of tranquilizers, sedatives, and sleeping pills, not inappropriate use of sedatives and hypnotics on its own. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Evidence 3 9 38 suggests that pharmacodynamic factors—such as selectivity for specific GABA A receptor subunits—and pharmacokinetic parameters—such as half-life and absorption rate—play a crucial role in determining the risk of dependence, withdrawal, and adverse effects associated with these agents.”
§ Z-drug abuse and dependence: clinical guideline of the Brazilian Academy of Neurology for diagnosis and management > CONSENSUS > Risk factors for Z-drug use disorder
What the sources say
- Partly supportedcites [3] N Gunja, 2013, The clinical and forensic toxicology of Z-drugs, J Med Toxicol sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [9] F Schifano, 2019, An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions, Int J Neuropsychopharmacol sourceExperimental — accuracy not yet measured
The Introduction’s “Clinical Pharmacological Issues” section says binding selectivity and pharmacokinetic profiles have been reported to reduce the possibility of sedation, dependence, and withdrawal, and it gives absorption and half-life figures. It does not identify specific GABA-A receptor subunits or establish that these factors play a crucial role in determining risk; the Discussion reports differences between drugs without demonstrating that mechanism. Page numbers are not available in our copy. (LLM, conf=0.85)
- Partly supportedcites [38] F De Crescenzo, 2022, Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis, Lancet sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Pharmacovigilance data show that zolpidem is the Z-drug most frequently linked to abuse, dependence, and withdrawal.”
§ Z-drug abuse and dependence: clinical guideline of the Brazilian Academy of Neurology for diagnosis and management > CONSENSUS > Z-drug use disorder
What the sources say
- Supportedcites [9] F Schifano, 2019, An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions, Int J Neuropsychopharmacol source
The Abstract Results report 23,420 zolpidem adverse-reaction reports relating to misuse, abuse, dependence, and withdrawal, versus 9,283 for zopiclone and 537 for zaleplon. The Discussion also identifies zolpidem as the most frequently reported Z-drug in the EudraVigilance dataset. This supports the claim about report frequency, not a claim that zolpidem has the highest risk for every outcome. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
85 more claims · 21 with their cited sources checked
Create a free account to see all 161 claims and to verify the 17 references still open.
- It may state two separate claims as one. 49
- Probably not a substantial claim. 26
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
Diamond, I. R., Grant, R. C., Feldman, B. M., Pencharz, P. B., Ling, S. C., Moore, A. M., & Wales, P. W. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.12.002 · Cited by 3,740
By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13702 · Cited by 2,609
Jünger, S., Payne, S. A., Brine, J., Radbruch, L., & Brearley, S. G. (2017) · Palliative Medicine · doi:10.1177/0269216317690685 · Cited by 2,210
Boulkedid, R., Abdoul, H., Loustau, M., Sibony, O., & Alberti, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020476 · Cited by 2,045 · cited 1×
“6,22,23 In practice, it involves selecting a panel of experts who anonymously respond to structured questionnaires across multiple rounds.”
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023
Riemann, D., Espie, C. A., Altena, E., Arnardottir, E. S., Baglioni, C., Bassetti, C. L. A., Bastien, C., Berzina, N., Bjorvatn, B., Dikeos, D., et al. (2023) · Journal of Sleep Research · doi:10.1111/jsr.14035 · Cited by 834
Krystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amato, D. A., Wessel, T. C., & Roth, T. (2003) · Sleep · doi:10.1093/sleep/26.7.793 · Cited by 630
Barrett, D., & Heale, R. (2020) · Evidence Based Nursing · doi:10.1136/ebnurs-2020-103303 · Cited by 510
Methodology Update: Delphi Studies
McPherson, S., Reese, C., & Wendler, M. C. (2018) · Nursing Research · doi:10.1097/nnr.0000000000000297 · Cited by 467
Research works printed but not linked: 7
- Agência Nacional de Vigilância Sanitária (Anvisa), 2024, Medicamento zolpidem terá alteração no tipo de receita para prescrição e venda
- W C Becker, 2025, Prescription drug misuse: Epidemiology, prevention, identification, and management
- 2023, FDA requiring lower recommended dose for certain sleep drugs containing zolpidem
- American Academy of Sleep Medicine, 2023, International Classification of Sleep Disorders – Third Edition, Text Revision (ICSD-3-TR)
- National Institute for Health and Care Excellence (NICE), 2022, Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults
- K Pottie, 2018, Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline, Can Fam Physician, 64, 339
- Kayser Permanente National Mediation Committee. National Permanente Medical Groups, 2021, Clinician Practice Recommendations for Benzodiazepines & Non-Benzodiazepines Sedative-Hypnotics/Z-Drugs (For Adults ≥ 18 Years Old)
Cited by
Ненадлежащее использование Z-препаратов: наиболее успешные стратегии преодоления. Обзор
Hmara, N. V., Pitsko, T. P., Ермоленко, В. А., & Шираани, А. Р. (2026) · Психиатрия психотерапия и клиническая психология · doi:10.34883/pi.2026.17.3.008
Metadata
- Authors
- Stelzer, F. G., Bacelar, A., Éckeli, A. L., Negrão, A. B., Almeida, C. M. O., Franco, C. M. R., Pires, G. N., Gitaí, L. L. G., Sobreira-Neto, M. A., Assis, M., Mei, P. A., Hasan, R., Martinez, S. C. G., Marchiori, T., Fidalgo, T. M., Siqueira, L. L. D., & Poyares, D.
- Affiliations
- Universidade de São Paulo (BR)
- Fundação Planetário da Cidade do Rio de Janeiro (BR)
- Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, Departamento de Neurociências e Ciências do Comportamento, Ribeirão Preto SP, Brazil.
- Universidade do Estado do Amazonas (BR)
- Universidade Federal de Pernambuco (BR)
- Instituto do Sono (BR)
- Centro Universitário Cesmac (BR)
- Universidade Federal do Ceará (BR)
- Hospital São Lucas, Curitiba PR, Brazil.
- Universidade Federal de São Carlos (BR)
- Hospital da Restauração (BR)
- Universidade Estadual de Campinas, Faculdade de Ciências Médicas, Departamento de Neurologia, Campinas SP, Brazil.
- ORCID
- Stelzer, Fernando Gustavo
- Bacelar, Andrea
- Éckeli, Alan Luiz
- Negrão, André Brooking
- Almeida, Carlos Maurício Oliveira
- Franco, Clélia Maria Ribeiro
- Pires, Gabriel Natan
- Gitaí, Lívia Leite Goés
- Sobreira-Neto, Manoel Alves
- Assis, Márcia
- Mei, Paulo Afonso
- Hasan, Rosa
- Martinez, Sandra Cristina Gonçalves
- Marchiori, Tania
- Fidalgo, Thiago M.
- Siqueira, Luciana L. de
- Poyares, Dalva
- Venue
- Arquivos de Neuro-Psiquiatria
- Publisher
- Georg Thieme Verlag KG
- Published
- 2025-10
- Volume
- 83
- Issue
- 10
- Pages
- 001-024
- ISSN
- 0004-282X (ISSN-L)
- 1678-4227
- PMC
- PMC12585905
- OpenAlex
- W4415892655
- Cited by
- 1
- References
- 90
- Citations by year
- 2026: 1
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Arquivos de Neuro-Psiquiatria (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- Z-drugs, benzodiazepine receptor agonists, hypnotic dependence, gradual tapering, cognitive behavioral therapy for insomnia, acceptance and commitment therapy, trazodone, gabapentinoids, melatonin, insomnia treatment, substance use disorders
- MeSH terms
- Benzodiazepines, Brazil, Humans, Hypnotics and Sedatives, Sleep Initiation and Maintenance Disorders, Substance Withdrawal Syndrome, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Z-drug abuse and dependence: clinical guideline of the Brazilian Academy of Neurology for diagnosis and management. https://app.cochat.ai/papers/10.1055/s-0045-1812323
- The paper
- Stelzer, F. G., Bacelar, A., Éckeli, A. L., Negrão, A. B., Almeida, C. M. O., Franco, C. M. R., Pires, G. N., Gitaí, L. L. G., Sobreira-Neto, M. A., Assis, M., Mei, P. A., Hasan, R., Martinez, S. C. G., Marchiori, T., Fidalgo, T. M., Siqueira, L. L. D., & Poyares, D. (2025). Z-drug abuse and dependence: clinical guideline of the Brazilian Academy of Neurology for diagnosis and management. Arquivos de Neuro-Psiquiatria. https://doi.org/10.1055/s-0045-1812323
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.